Halma plc (“Halma”) has sold its subsidiary Cardios Sistemas Comercial e Industrial Ltda. and Cardios Dinâmica Ltda. (“Cardios”), a Brazil-based designer and manufacturer of digital Holter recorders and ambulatory blood pressure monitors, to Cardioline Holding S.p.A (“Cardioline”), a portfolio company of ARCHIMED SAS (“ARCHIMED”). Cardios is a leading provider of Holter monitoring and ambulatory blood pressure monitoring (ABPM) solutions, built on decades of clinical expertise and a trusted reputation among healthcare providers. Known for their reliability and proximity to the clinical market, Cardios has become a reference in long-term cardiac monitoring for patients and institutions across Brazil.
About Halma
Halma (LON:HLMA) is listed on the London Stock Exchange and is a constituent of the FTSE 100 operating in the fields of Safety, Environment and Health. Halma employs over 8,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific.
About Cardioline
Cardioline is a globally recognized manufacturer of cardiac diagnostic equipment, specializing in ECG systems, stress testing platforms, and integrated cardiology solutions. With a legacy of innovation spanning decades, Cardioline serves healthcare professionals and institutions across more than 85 countries globally, delivering technology that advances clinical precision and patient outcomes. Cardioline is a portfolio company of ARCHIMED.
About ARCHIMED
With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Services and MedTech. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €9 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.
EC M&A acted as exclusive financial advisor to Halma on this transaction. This transaction also represents the 12th transaction with Halma.
